Mottahedin A: Difference between revisions
From Bioblast
No edit summary |
Beno Marija (talk | contribs) Β |
||
(One intermediate revision by one other user not shown) | |||
Line 10: | Line 10: | ||
{{Labelingperson}} | {{Labelingperson}} | ||
==Participated at== | ==Participated at== | ||
*[[ | ::::* [[IOC115 | IOC115 Schroecken AT]] |
Latest revision as of 11:55, 14 February 2018
Name | Mottahedin Amin, |
---|---|
Institution | University of Gothenburg |
Address | Medicineregatan 11, |
City | Gothenburg |
State/Province | |
Country | Sweden |
[email protected] | |
Weblink | |
O2k-Network Lab | SE Gothenburg Hagberg H |
Labels:
Publications
Published | Reference | |
---|---|---|
Yin 2021 Nat Commun | 2021 | Yin Z, Burger N, Kula-Alwar D, AksentijeviΔ D, Bridges HR, Prag HA, Grba DN, Viscomi C, James AM, Mottahedin A, Krieg T, Murphy MP, Hirst J (2021) Structural basis for a complex I mutation that blocks pathological ROS production. Nat Commun 12:707. |
Mottahedin 2017 J Cereb Blood Flow Metab | 2017 | Mottahedin A, Svedin P, Nair S, Mohn CJ, Wang X, Hagberg H, Ek J, Mallard C (2017) Systemic activation of Toll-like receptor 2 suppresses mitochondrial respiration and exacerbates hypoxic-ischemic injury in the developing brain. J Cereb Blood Flow Metab 37:1192-8. |